Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker ADCT · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Jul 20, 2026 | A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With… NCT05660395 · Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma Loncastuximab Tesirine | ADCT ADC Therapeutics S.A. | Phase 1 | Terminated | 5 | Jun 25, 2026 | Registry ↗ |
| Jul 17, 2026 | A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination Wi… NCT04970901 · B-Cell Non-Hodgkin Lymphoma, Relapsed B-Cell Non-Hodgkin Ly… Loncastuximab Tesirine, Polatuzumab Vedotin | ADCT ADC Therapeutics S.A. | Phase 1 | Active, not recruiting | 154 | Mar 31, 2027 | Registry ↗ |
| Apr 28, 2026 | Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants W… NCT04384484 · Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse… Loncastuximab Tesirine, Rituximab | ADCT ADC Therapeutics S.A. | Phase 3 | Active, not recruiting | 440 | Mar 31, 2026 | Registry ↗ |
| May 22, 2025 | A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors NCT05389462 · Advanced Solid Tumors ADCT-601, Gemcitabine | ADCT ADC Therapeutics S.A. | Phase 1 | Terminated | 128 | Apr 17, 2025 | Registry ↗ |
| May 22, 2025 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901… NCT04972981 · Advanced Solid Tumors ADCT-901 | ADCT ADC Therapeutics S.A. | Phase 1 | Completed | 30 | Sep 13, 2024 | Registry ↗ |
| Jan 30, 2025 | A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Parti… NCT05144009 · Diffuse Large B-cell Lymphoma Loncastuximab Tesirine, Rituximab | ADCT ADC Therapeutics S.A. | Phase 2 | Terminated | 41 | Jan 22, 2024 | Registry ↗ |
| Jun 13, 2024 | Study of ADCT-301 in Patients With Selected Advanced Solid Tumors NCT03621982 · Head and Neck Cancer Squamous Cell Carcinoma, Non-small Cel… ADCT-301, Pembrolizumab | ADCT ADC Therapeutics S.A. | Phase 1 | Terminated | 78 | Dec 14, 2022 | Registry ↗ |
| Mar 28, 2024 | Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Rela… NCT04052997 · Relapsed Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Camidanlumab Tesirine | ADCT ADC Therapeutics S.A. | Phase 2 | Completed | 117 | Jan 19, 2023 | Registry ↗ |
| Feb 6, 2024 | Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle C… NCT03684694 · Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma Loncastuximab Tesirine, Ibrutinib | ADCT ADC Therapeutics S.A. | Phase 1/2 | Terminated | 136 | Nov 8, 2022 | Registry ↗ |
| Oct 23, 2023 | Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participan… NCT04699461 · Relapsed Follicular Lymphoma, Refractory Follicular Lymphoma Loncastuximab Tesirine, Idelalisib | ADCT ADC Therapeutics S.A. | Phase 2 | Terminated | 6 | Nov 25, 2022 | Registry ↗ |
| Aug 29, 2023 | Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Re… NCT03589469 · Diffuse Large B-Cell Lymphoma Refractory, Diffuse Large B-c… Loncastuximab tesirine | ADCT ADC Therapeutics S.A. | Phase 2 | Completed | 145 | May 24, 2020 | Registry ↗ |
| Jun 22, 2022 | Long-term Registry of Patients Treated With Loncastuximab Tesirine NCT05160064 · B-Cell Lymphomas | ADCT ADC Therapeutics S.A. | — | Withdrawn | 0 | Dec 2024 | Registry ↗ |
| Mar 29, 2022 | A Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of Loncastux… NCT04974996 · Diffuse Large B-Cell Lymphoma Loncastuximab tesirine, Prednisone | ADCT ADC Therapeutics S.A. | Phase 1 | Withdrawn | 0 | Mar 11, 2024 | Registry ↗ |
| Oct 26, 2021 | Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cel… NCT03685344 · Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma Loncastuximab Tesirine and Durvalumab | ADCT ADC Therapeutics S.A. | Phase 1 | Terminated | 13 | Oct 27, 2020 | Registry ↗ |
| Jul 13, 2021 | Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma NCT02432235 · Hodgkin Lymphoma, Non-Hodgkin Lymphoma Camidanlumab tesirine | ADCT ADC Therapeutics S.A. | Phase 1 | Completed | 133 | Oct 24, 2019 | Registry ↗ |
| May 24, 2021 | Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukem… NCT02669264 · Acute Lymphoblastic Leukemia ADCT-402 | ADCT ADC Therapeutics S.A. | Phase 1 | Terminated | 35 | Jul 3, 2018 | Registry ↗ |
| May 19, 2021 | Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NH… NCT02669017 · Non-Hodgkin Lymphoma, Burkitt's Lymphoma ADCT-402 | ADCT ADC Therapeutics S.A. | Phase 1 | Completed | 183 | Feb 21, 2019 | Registry ↗ |
| May 12, 2021 | Loncastixumab Tesirine (ADCT-402) Expanded Access Program (EAP) for Patients With Relapsed/Refracto… NCT04705454 · Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R D… Loncastuximab Tesirine | ADCT ADC Therapeutics S.A. | — | No longer available | — | — | Registry ↗ |
| Feb 1, 2021 | Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth Factor Receptor… NCT03125200 · Breast Cancer, Non Small Cell Lung Cancer ADCT-502 | ADCT ADC Therapeutics S.A. | Phase 1 | Terminated | 21 | Apr 5, 2018 | Registry ↗ |
| May 1, 2020 | Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tum… NCT03700294 · Advanced Solid Tumors ADCT-601 | ADCT ADC Therapeutics S.A. | Phase 1 | Terminated | 18 | Dec 11, 2019 | Registry ↗ |
| Feb 26, 2020 | Study of ADCT-301 in Patients With Relapsed/Refractory CD25-positive Acute Myeloid Leukemia (AML) o… NCT02588092 · Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia ADCT-301 | ADCT ADC Therapeutics S.A. | Phase 1 | Terminated | 35 | Aug 29, 2018 | Registry ↗ |
21 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:00 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances